1118 Chess Drive
About Orchard Therapeutics
Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to transforming the lives of patients with rare disorders through innovative gene therapies
Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders
We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy
Our mission is to be a leading global, fully integrated company delivering innovative gene therapies that transform the lives of patients with rare disorders
29 articles with Orchard Therapeutics
Four months after acquiring GlaxoSmithKline’s rare disease gene therapy portfolio, U.K.-based Orchard Therapeutics secured $150 million in an oversubscribed Series C funding round. The funds will be used to advance three late-stage programs that it gained from the deal with GSK.
Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing.
Orchard Therapeutics, a leading commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the appointment of Jon Ellis, Ph.D. as GSK’s designated representative to its board of directors.
7/16/2018With the Independence Day holiday in the rearview mirror, numerous biopharma companies continued to adjust their leadership ranks and strengthen the members of various boards representing and overseeing the companies.
Orchard Therapeutics, today announced the appointment of Joanne Beck, Ph.D., to its board of directors.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
With the end of June, numerous biotechs shored up their boards of directors and other advisory boards with new members as the companies continued to shape their future strategies.
A new report highlights some concerns about the long-term commercial viability of game-changing gene therapies that can radically transform the lives of patients.
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
Imara Inc. today announced additions to its clinical development team with the appointments of Joe Datt, M.D., as Senior Vice President, Clinical Development, and Siddharth Parulkar as Head, Global Clinical Operations.
Despite strong sales of shingles vaccine Shingrix, GlaxoSmithKline reported its sales and earnings fell 2 percent in the first quarter of the year, largely due to challenges in respiratory sales as well as significant currency impact.
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to trim excess fat from the company. This morning the company announced it has divested its rare disease gene therapy portfolio to Orchard Therapeutics.
Dr. Malech is a globally recognized expert in primary immune deficiencies and gene therapy.
Orchard Therapeutics today announced the appointment of Frank Thomas to the newly created position of CFO and CBO.
Orchard Therapeutics today announced that Mark Rothera, president and CEO, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 9, 2018 at 3:00 p.m. PT.
12/20/2017Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund.
Yposkesi Has Been Selected by Orchard Therapeutics to Produce Lentiviral Gene Therapy Vectors For Clinical Trials
As part of this partnership, Yposkesi will produce lentiviral vector batches to meet Orchard's needs for clinical trials in primary immune deficiencies including X-linked chronic granulomatous disease.
Orchard Therapeutics and Généthon Announce Gene Therapy Alliance in X-Linked Chronic Granulomatous Disease
X-linked CGD is a primary immune deficiency resulting from a mutation on the X-chromosome and affecting mainly boys.
Orchard today announced the opening of a second facility for technical operations in the San Francisco Bay Area.